Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Ophthalmology Drugs Market Global Briefing 2017

Ophthalmology Drugs Market Global Briefing 2017

From $1,000.00

Including: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs.
Covering: Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc., Valeant Pharmaceuticals Intl Inc., Bayer AG, Santen Pharmaceutical Co., Ltd., Gilead, Otsuka Pharmaceutical Co., Ltd., Shire Plc.


Clear selection
SKU: 2278. Categories: , .
Description

The top segments in the opthalmology drugs market include other opthalmological drugs accounting for around 60% share of the market. Antiglaucoma drugs accounting for around 26% of the market. Dry Eye Medication was the smalllest segment accounting for 14% of the market.

Opthalmalogy Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the opthalmalogy drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the opthalmalogy drugs market and suggests approaches.

Reasons to Purchase

• Get up to date information available on the opthalmalogy drugs market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.

 

Scope

Markets Covered: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs.
Companies Mentioned: Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc., Valeant Pharmaceuticals Intl Inc., Bayer AG, Santen Pharmaceutical Co., Ltd., Gilead, Otsuka Pharmaceutical Co., Ltd., Shire Plc.
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

 

Executive Summary
The ophthalmology drugs market covers drugs that are used in the treatment of eye related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and macular degeneration. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax.

The global ophthalmology drugs market is expected to reach around $33 billion in 2020. This can be attributed to the expected rise in prevalence of eye conditions such as age-related macular degeneration (AMD), diabetic retinopathy and glaucoma that require ophthalmology drugs.

Rho-Kinase Inhibitors In Glaucoma Treatment - Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression. These inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition. Major Rho-kinase inhibitors being developed include ATS907, ATS8535, AR-12286, AR-13324, AMA0076 and BOL-303259-X.
Table of Contents
Ophthalmology Drugs Market Characteristics 5
Ophthalmology Drugs Market Historic Growth 6
Ophthalmology Drugs Market Forecast Growth 7
Ophthalmology Drugs Market Segmentation 8
Global Ophthalmology Drugs Market, Split By Segments, 2016, $ Billion 8
Other Opthalmological Drugs 9
Antiglaucoma 9
Dry Eye Medication 9
Global Ophthalmology Drugs Market, Historic and Forecast, Split By Segments, 2012-2020 10
Ophthalmology Drugs Market Geography Regional and Country Comparison 12
Global Ophthalmology Drugs Market, Split By Regions, 2016 12
Global Ophthalmology Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 14
Global Ophthalmology Drugs Market, Split By Country, 2016 16
Global Ophthalmology Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 18
Ophthalmology Drugs Market Competitive Landscape 20
Novartis AG 21
F. Hoffmann-La Roche Ltd. 21
Allergan Plc. 21
Valeant Pharmaceuticals Intl Inc. 21
Bayer AG 21
Gilead 21
Santen Pharmaceutical Co., Ltd. 21
Otsuka Pharmaceutical Co., Ltd. 21
Shire Plc. 21
Novartis AG 22
F.Hoffmann-La Roche 22
Allergan 23
Ophthalmology Drugs Market Key Mergers And Acquisitions 24
Actavis Plc. Acquired Allergan Inc. 24
Santen Pharmaceutical Acquired Merck’s Ophthalmology Products 24
Astellas Pharma Acquired Ocata Therapeutics 24
Horizon Pharma Acquired River Vision Development Corp. 24
Sun Pharma Acquired InSite Vision 24
Novartis Acquired Encore Vision 24
Purdue Canada Acquired Merck’s Ophthalmology Portfolio 25
Lupin Acquired Laboratorios Grin 25
Ophthalmology Drugs Market Trends And Strategies 26
Rho-Kinase Inhibitors In Glaucoma Treatment 26
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) For Dry Eye Treatment 26
Development Of Combination Therapies 26
Appendix 28
Definition Of Market Covered In This Report 28
Abbreviations 28
Currencies 28
Research Methodology 28
Research Inquiries 29
The Business Research Company 30

List of Figures
Figure 1: Global Ophthalmology Drugs Market, Historic Market Size, 2012-2016, $ Billion 6
Figure 2: Global Ophthalmology Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 7
Figure 3: Global Ophthalmology Drugs Market, Split By Segments, 2016, $ Billion 8
Figure 4: Global Ophthalmology Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 10
Figure 5: Global Ophthalmology Drugs Market, Split By Region, 2016, $ Billion 12
Figure 6: Global Ophthalmology Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 14
Figure 7: Global Ophthalmology Drugs Market, Split By Country, 2016, $ Billion 16
Figure 8: Global Ophthalmology Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 18
Figure 9: Global Ophthalmology Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 20

List of Tables
Table 1: Global Ophthalmology Drugs Market, Historic Market Size, 2012-2016, $ Billion 6
Table 2: Global Ophthalmology Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 7
Table 3: Global Ophthalmology Drugs Market, Split By Segments, 2016, $ Billion 8
Table 4: Global Ophthalmology Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 10
Table 5: Global Ophthalmology Drugs Market, Split By Region, 2016, $ Billion 13
Table 6: Global Ophthalmology Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 14
Table 7: Global Ophthalmology Drugs Market, Split By Country, 2016, $ Billion 17
Table 8: Global Ophthalmology Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 18
Table 9: Global Ophthalmology Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 21
Get Customized Report
Please fill in your details. Our team will get back to you